Table 1 Clinical backgrounds of the HS group
From: Eicosapentaenoic Acid as long-term secondary prevention after ischemic stroke
ICH | ICH + BI | BI + ICH | |
|---|---|---|---|
N | 6 | 2 | 2 |
Sex (F/M) | 1/5 | 0/2 | 2/0 |
Age | 63.5 ± 10.4 | 78.5 ± 9.2 | 71.0 ± 7.1 |
EPA (mg) | 1950 ± 677 | 2288 ± 636 | 2372 ± 636 |
Length (years) | 2.4 ± 1.0 | 5.1 ± 1.8 | 2.6 ± 0.6 |
Hypertension (%) | 100 | 100 | 100 |
Hyperlipidemia (%) | 83.3 | 50 | 100 |
DM (%) | 16.7 | 0 | 100 |
Af (%) | 16.7 | 0 | 0 |
TCho (mg/dl) | 198.2 ± 21.5 | 157.0 ± 22.6 | 186.5 ± 57.3 |
LDL (mg/dl) | 120.2 ± 18.6 | 87.0 ± 7.1 | 117.5 ± 57.3 |
TG (mg/dl) | 89.5 ± 33.7 | 76.0 ± 18.4 | 100.0 ± 4.2 |
Cre (mg/dl) | 0.7 ± 0.1 | 0.8 ± 0.1 | 0.7 ± 0.1 |
eGFR (ml/min/1.73 m2) | 79.6 ± 11.9 | 76.2 ± 5.5 | 64.4 ± 16.1 |
AP, single (%) | 0 | 0 | 50 |
AP, multi (%) | 16.7 | 0 | 0 |
Warfarin (%) | 16.7 | 0 | 0 |
W + AP (%) | 0 | 50 | 0 |
None (%) | 66.7 | 50 | 50 |